FDA updates on angiotensin II receptor blocker (ARB) recalls including valsartan, losartan and irbesartan IMPORTANT: Medications containing only amlodipine or hydrochlorothiazide (HCTZ) are not being recalled. Manufacturers are recalling medications containing amlodipine in combination with valsartan or losartan, and medications containing hydrochlorothiazide HCTZ in combination with valsartan or losartan. […]
A U.S. Food and Drug Administration (FDA) review found that fluoroquinolone antibiotics can increase the occurrence of rare but serious events of ruptures or tears in the main artery of the body, called the aorta. These tears, called aortic dissections, or ruptures of an aortic aneurysm can lead to dangerous bleeding or even death.
Torrent Pharmaceuticals Limited is voluntarily recalling 2 lots of Losartan potassium tablets, USP to the consumer level due to the detection of trace amounts of a probable human carcinogen.
UPDATE – More blood pressure medications added to what is NOW a global recall for potential cancer risk: [11/29/2018] Teva Pharmaceuticals has launched a voluntary recall into two drugs used to treat high blood pressure as yet more medications face concerns over a possible cancer risk. In a statement from Teva posted [...]
The recall has spread globally with Health Canada and the European Medicines Agency having also recalled drugs using valsartan provided by Zhejiang Huahai. The valsartan tablets (dosages 40mg to 320mg) the FDA has recalled include products from the following drug companies: A-S Medication Solutions (labeled as Solco Healthcare) Bryant Ranch Prepack HJ Harkins Company Northwind [...]
Product Quest Manufacturing LLC Issues Voluntary Nationwide Recall of CVS Health 12 Hour Sinus Relief Nasal Mist Due to Microbiological Contamination. For Immediate Release August 8, 2018 Contact Consumers Joan Sanger, Site Head of Quality 386-239-8787 Announcement View Product Photos Holly Hill, FL, Product Quest Manufacturing (“Product Quest”) is voluntarily recalling Lot# 173089J of CVS [...]
FDA is requiring a new class warning and other safety measures for all gadolinium-based contrast agents (GBCAs) for magnetic resonance imaging (MRI) concerning gadolinium remaining in patients’ bodies, including the brain, for months to years after receiving these drugs.
Generic drugs may not provide an adequate level of protection to the patient.
On November 16th 2017, a federal jury in Dallas, TX told Johnson & Johnson and their subsidiary DePuy that they need to pay six patients a total of $247 million due to hip implants that turned out to be defective. The verdict came as a result of finding that the hip implants used a metal [...]